Company Overview of Durata Therapeutics, Inc.
Durata Therapeutics, Inc., a pharmaceutical company, focuses on the development and commercialization of novel therapeutics for patients with infectious diseases and acute illnesses. Its principal product includes dalbavancin, an intravenous antibiotic product candidate, which has completed Phase 3 clinical trials for the treatment of patients with acute bacterial skin and skin structure infections. The company was founded in 2009 and is headquartered in Chicago, Illinois. As of November 14, 2014, Durata Therapeutics, Inc. operates as a subsidiary of Actavis W.C. Holding Inc.
200 Sourth Wacker Drive
Chicago, IL 60606
Founded in 2009
Key Executives for Durata Therapeutics, Inc.
Durata Therapeutics, Inc. Key Developments
Similar Private Companies By Industry
|20n Labs, Inc.||United States|
|23andMe, Inc.||United States|
|2C Tech Corporation, Inc.||United States|
|3-V Biosciences, Inc.||United States|
|3D Bio Holdings LLC||United States|
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
Most Searched Private Companies
|Company Name||Geographic Region|
|Lawyers Committee for Civil Rights Under Law||United States|
|NYC2012, Inc.||United States|
|Rush University||United States|
|Bloomberg L.P.||United States|
Sponsored Financial Commentaries
To contact Durata Therapeutics, Inc., please visit www.duratatherapeutics.com. Company data is provided by Capital IQ. Please use this form to report any data issues.